Targeting only one of several important subtypes of receptors such as those of endothelin-1, serotonin or angiotensin II separately in clinical or experimental trials might prevent cerebral ischemia to a certain degree as seen in the literature, but treatments aimed at a common signaling pathway would be more beneficial since further possible receptors and inflammatory mechanisms might be involved. This evidence concerns the gene EDN1 and brain ischemia.